JAIC
WGS icon

Josh Arnold Investment Consultant’s GeneDx Holdings WGS Stock Holding History

Josh Arnold Investment Consultant’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-630
Closed -$8K – 33
2023
Q1 		$8K Buy
+630
New +$8.4K 0.01% 16

Other funds holding WGS

CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Josh Arnold Investment Consultant's WGS Position: Q2 2023 in Review

Josh Arnold Investment Consultant sold out of GeneDx Holdings (WGS) in Q2 2023, closing a stake of 630 shares — an estimated $8K sold.

Josh Arnold Investment Consultant first reported a position in WGS in Q1 2023 and held it in 1 quarter. The position peaked at $8K in Q1 2023. 58 funds tracked by Wall St. Rank hold WGS as of Q2 2023.

  • Josh Arnold Investment Consultant reported no remaining GeneDx Holdings position as of Q2 2023 after selling out during the quarter.
  • Josh Arnold Investment Consultant sold 630 GeneDx Holdings shares in Q2 2023, an estimated $8K.
  • Josh Arnold Investment Consultant first reported a position in GeneDx Holdings in Q1 2023 and held it in 1 quarter.
  • Josh Arnold Investment Consultant's GeneDx Holdings position peaked at $8K in Q1 2023.
  • 58 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2023.

Based on Josh Arnold Investment Consultant's 13F filing for Q2 2023, filed 14 Aug 2023.